For example, the dual GIP and GLP-1 RA tirzepatide at 5-15 mg was shown to be superior to basal insulin and to 1 mg of semaglutide weekly in reducing levels of hemoglobin A1c (HbA1c) and body weight in patients with overweight or obesity and T2D [11,12]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.